Emesis
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Emesis</strong> (Vomiting) - Pipeline Review, H2 2015 Is<br />
Released<br />
<strong>Emesis</strong> (Vomiting) - Pipeline Review, H2 2015 Summary Global Markets Direct s, <strong>Emesis</strong> (Vomiting) -<br />
Pipeline Review, H2 2015, provides an overview of the <strong>Emesis</strong> (Vomiting)s therapeutic pipeline. This<br />
report provides comprehensive information on the therapeutic development for <strong>Emesis</strong> (Vomiting),<br />
complete with comparative analysis at various stages, therapeutics assessment by drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,<br />
and featured news and press releases. It also reviews key players involved in the therapeutic<br />
development for <strong>Emesis</strong> (Vomiting) and special features on late-stage and discontinued projects. Global<br />
Markets Directs report features investigational drugs from across globe covering over 20 therapy areas<br />
and nearly 3,000 indications. The report is built using data and information sourced from Global Markets<br />
Directs proprietary databases, Company/University websites, SEC filings, investor presentations and<br />
featured press releases from company/university sites and industry-specific third party sources, put<br />
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes<br />
periodic updation following a stringent set of processes that ensures that all the profiles are updated<br />
with the latest set of information. Additionally, processes including live news & deals tracking, browser<br />
based alert-box and clinical trials registries tracking ensure that the most recent developments are<br />
captured on a real time basis. The report enhances decision making capabilities and help to create<br />
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying<br />
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the<br />
report may be removed or altered based on the availability and relevance of data for the indicated<br />
disease. Scope - The report provides a snapshot of the global therapeutic landscape of <strong>Emesis</strong> (Vomiting)<br />
- The report reviews key pipeline products under drug profile section which includes, product<br />
description, MoA and R&D brief, licensing and collaboration details & other developmental activities -<br />
The report reviews key players involved in the therapeutics development for <strong>Emesis</strong> (Vomiting) and<br />
enlists all their major and minor projects - The report summarizes all the dormant and discontinued<br />
pipeline projects - A review of the <strong>Emesis</strong> (Vomiting) products under development by companies and<br />
universities/research institutes based on information derived from company and industry-specific<br />
sources - Pipeline products coverage based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages - A detailed assessment of monotherapy and<br />
combination therapy pipeline projects - Coverage of the <strong>Emesis</strong> (Vomiting) pipeline on the basis of<br />
target, MoA, route of administration and molecule type - Latest news and deals relating related to<br />
pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,<br />
and insights to formulate effective R&D development strategies - Identify emerging players with<br />
potentially strong product portfolio and create effective counter-strategies to gain competitive<br />
advantage - Develop strategic initiatives by understanding the focus areas of leading companies -<br />
Identify and understand important and diverse types of therapeutics under development for <strong>Emesis</strong><br />
(Vomiting) - Plan mergers and acquisitions effectively by identifying key players of the most promising<br />
pipeline - Devise corrective measures for pipeline projects by understanding <strong>Emesis</strong> (Vomiting) pipeline<br />
depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies<br />
by identifying prospective partners with the most attractive projects to enhance and expand business<br />
1
potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and<br />
understanding the factors that drove them from pipeline.<br />
Browse with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173380/emesisvomiting-pipeline-review-h2-2015<br />
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173380/emesis-vomiting-pipeline-review-h2-2015<br />
Table of Contents<br />
Introduction 5<br />
Global Markets Direct Report Coverage 5<br />
<strong>Emesis</strong> (Vomiting) Overview 6<br />
Therapeutics Development 7<br />
Pipeline Products for <strong>Emesis</strong> (Vomiting) - Overview 7<br />
Pipeline Products for <strong>Emesis</strong> (Vomiting) - Comparative Analysis 8<br />
<strong>Emesis</strong> (Vomiting) - Therapeutics under Development by Companies 9<br />
<strong>Emesis</strong> (Vomiting) - Therapeutics under Investigation by Universities/Institutes 10<br />
<strong>Emesis</strong> (Vomiting) - Pipeline Products Glance 11<br />
Clinical Stage Products 11<br />
Early Stage Products 12<br />
<strong>Emesis</strong> (Vomiting) - Products under Development by Companies 13<br />
<strong>Emesis</strong> (Vomiting) - Products under Investigation by Universities/Institutes 14<br />
<strong>Emesis</strong> (Vomiting) - Companies Involved in Therapeutics Development 15<br />
Daewoong Pharmaceutical Co., Ltd. 15<br />
Epiomed Therapeutics, Inc. 16<br />
InteguRx Therapeutics, LLC 17<br />
<strong>Emesis</strong> (Vomiting) - Therapeutics Assessment 18<br />
Assessment by Monotherapy Products 18<br />
Assessment by Target 19<br />
2
Assessment by Mechanism of Action 21<br />
Assessment by Route of Administration 23<br />
Assessment by Molecule Type 25<br />
Drug Profiles 27<br />
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 27<br />
Product Description 27<br />
Mechanism of Action 27<br />
R&D Progress 27<br />
DWJ-1308 - Drug Profile 28<br />
Product Description 28<br />
Mechanism of Action 28<br />
R&D Progress 28<br />
ETI-385 - Drug Profile 29<br />
Product Description 29<br />
Mechanism of Action 29<br />
R&D Progress 29<br />
granisetron hydrochloride SR - Drug Profile 30<br />
Product Description 30<br />
Mechanism of Action 30<br />
R&D Progress 30<br />
NEO-1940 - Drug Profile 31<br />
Product Description 31<br />
Mechanism of Action 31<br />
R&D Progress 31<br />
ondansetron hydrochloride - Drug Profile 32<br />
Product Description 32<br />
Mechanism of Action 32<br />
3
R&D Progress 32<br />
<strong>Emesis</strong> (Vomiting) - Dormant Projects 33<br />
<strong>Emesis</strong> (Vomiting) - Discontinued Products 34<br />
Appendix 35<br />
Methodology 35<br />
Coverage 35<br />
Secondary Research 35<br />
Primary Research 35<br />
Expert Panel Validation 35<br />
Contact Us 35<br />
Disclaimer 36<br />
Read More http://www.idatainsights.com/reports-landing-page.php?id=173380/emesis-vomitingpipeline-review-h2-2015<br />
About Us:<br />
iData Insights which operates under Precision Research and Consulting Private Limited is a leading<br />
market research information aggregator and marketing research consulting firm. We conduct both<br />
primary and secondary research. Our work does not end with research it is also involved in distributing<br />
reports for different companies . We provide actionable recommendations and provide our expertise for<br />
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and<br />
discovery, and then be their guide in the implementation of changes that will make a difference to their<br />
bottom line.<br />
ContactUs:<br />
iData Insights<br />
Tel: 1-866-237-2965<br />
Web: http://www.idatainsights.com<br />
Email: info@idatainsights.com<br />
About iData Insights<br />
We work around the clock until our clients are completely satisfied with their promised results. It is our<br />
mission to provide timely services coupled with acute client care to create a long-lasting relationship<br />
with you. We deliver on our promise to provide results that are essential to the success of your<br />
company. We believe that by doing so, we will earn the trust of our clients for future projects<br />
4
5
Change language